Memo Therapeutics Funding: $69M Raised, Series C (2023)
Memo Therapeutics is based in Schlieren / Zurich, Switzerland. It has raised $69M in total funding. Latest round: Series C.
Memo Therapeutics funding overview
Memo Therapeutics is based in Schlieren / Zurich, Switzerland. Memo Therapeutics has raised $69M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series C announced in November 2023. The round record for Memo Therapeutics runs through 2023; nothing later has been disclosed. Investors on record include Pureos Bioventures, Swisscanto Invest, Vesalius Biocapital, Adjuvant Capital, Verve Ventures, Schroders Capital and 8 others. 14 distinct backers are named across the disclosed rounds.
Memo Therapeutics at a glance
Total raised
$69M
Latest round
Series C
Latest round date
November 2023
Headquarters
Schlieren / Zurich, Switzerland
Notable investors
Pureos Bioventures, Swisscanto Invest, Vesalius Biocapital, Adjuvant Capital, Verve Ventures, Schroders Capital, GF Group, Fresenius Medical Care Ventures
Frequently asked about Memo Therapeutics funding
How much has Memo Therapeutics raised?
Memo Therapeutics has raised $69M in total disclosed funding across the rounds on record.
Who has invested in Memo Therapeutics?
Pureos Bioventures, Swisscanto Invest, Vesalius Biocapital, Adjuvant Capital, Verve Ventures, Schroders Capital are named among the investors backing Memo Therapeutics.
What was the latest Memo Therapeutics funding round?
The most recent disclosed round is a Series C, announced in November 2023.
Where is Memo Therapeutics based?
Memo Therapeutics is based in Schlieren / Zurich, Switzerland.
When did Memo Therapeutics last raise?
The last disclosed Memo Therapeutics round closed in November 2023 at Series C.
Totals shown for Memo Therapeutics aggregate every disclosed round on file. To see how that compares, browse the companies in Schlieren / Zurich and the investors behind them below.
